Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study.1 The study met all primary endpoints, showing that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years.2 Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sight, and allow extended time between treatments in people with DME.2 These data were presented in a late-breaking oral presentation at The American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden.2

Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Novo Nordisk (NVO) lower Wednesday.

Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise

Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.

Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug

Eli Lilly

Novo Nordisk

The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.

Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.

Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk

Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.

Roche shares jump on drugmaker's early-stage data on weight-loss drug

Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk and Eli Lilly in the burgeoning diabetes and obesity drug market amid growing evidence the drugs can treat many other health conditions like kidney disease and sleep apnea.

Roche Climbs As Once-Daily Weight Loss Pill Shows Promise

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.

Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche

Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.

Roche reports positive early results in CT-966 obesity drug trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.1 The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinical.

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.1 The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to $1 billion in milestone payments and royalties WATERTOWN, Mass. , July 10, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced that it has attained the near-term milestone as part of its collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.

Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration

MALVERN, Pa.--(BUSINESS WIRE)--The Institutes have appointed W. Robert Berkley Jr. as chair, and John C. (Jack) Roche as vice chair, of the organization's Board of Trustees.

W. Robert Berkley and John C. Roche Named Chair and Vice Chair of The Institutes Board of Trustees

Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.

Roche reintroduces recalled eye implant in US

Basel, 08 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (US) with neovascular or ‘wet' age-related macular degeneration (nAMD), following the end of a voluntary recall. The US Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle. Roche will work to make Susvimo available in the US to retina specialists and their patients with nAMD in the coming weeks.

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (U.S.) with wet, or neovascular, age-related macular degeneration (AMD), following the end of a voluntary recall. The U.S. Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics.

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to 80 million people globally.1-4 The Vabysmo PFS will become available to United States (US) retina specialists and their patients in the coming months.

FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) has approved the Vabysmo® (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to three million.

FDA Approves Genentech's Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co , casting further doubt on the drug candidate pioneered by the Swiss company.

Roche to halt trial in latest setback for lung cancer immunotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progre.

Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

Basel, 04 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes the phase II and phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting.

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

News for Roche Holding AG Stock (RHHBY)